A prospective, open-label, multi-center, post marketing study to evaluate safety and efficacy of fixed dose combination (FDC) tablets of arterolane maleate and piperaquine phosphate (PQP) in Indian patients with acute uncomplicated falciparum malaria.

Trial Profile

A prospective, open-label, multi-center, post marketing study to evaluate safety and efficacy of fixed dose combination (FDC) tablets of arterolane maleate and piperaquine phosphate (PQP) in Indian patients with acute uncomplicated falciparum malaria.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Arterolane/piperaquine (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Sponsors Ranbaxy Laboratories
  • Most Recent Events

    • 19 Mar 2014 Status changed from recruiting to completed, as per Clinical Trials Registry - India record.
    • 25 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top